CFPC Accreditation: Earn up to 9.25 Mainpro+® Certified Activity credits.
RCPSC Accreditation: This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada and approved by the University of Calgary Office of Continuing Medical Education and Professional Development. This activity has been approved for a maximum of 10 hours (credits are automatically calculated).
AAFP & AMA: Reciprocal credits available
| Time | Topic | Speaker(s) |
|---|---|---|
| 12:00 PM | Welcome and opening remarks and guest speaker introductions | |
| 12:10 PM | Opening Keynote: The evolution of obesity – fate vs personal failure Learning Objective Examine the biological and environmental factors that drive obesity to reframe it as a complex disease beyond individual willpower. |
Kirsi Pietiläinen |
| 12:45 PM | The pathophysiology of obesity Learning Objective Describe the key physiological mechanisms of obesity and explain how they contribute to the development and maintenance of obesity. |
Sean Wharton |
| 01:03 PM | Sex differences in obesity and cardiometabolic disease Learning Objective Describe how obesity and cardiometabolic disease prevalence and presentation differ between sexes. |
Sasha High |
| 01:21 PM | Hyperphagia: diagnosis and management Learning Objective Define hyperphagia and discuss evidence-based approaches for diagnosing and managing hyperphagia in clinical practice, including the screening and diagnosis of rare genetic obesity disorders such as Bardet-Biedl Syndrome (BBS). |
Satya Dash |
| 01:39 PM | Sarcopenia: adipose tissue and muscle cross-talk Learning Objective Explain the pathophysiological relationship between adipose tissue and skeletal muscle and its implications for obesity management, including the recognition of sarcopenia, strategies for muscle preservation, and approaches for monitoring and supporting muscle health. |
Michael Tsoukas |
| 02:20 PM | Break | |
| 02:50 PM | Introduction: Incretins and outcomes: What have we learned? | |
| 02:55 PM | Obesity Learning Objective Evaluate the efficacy, safety, and clinical applications of GLP-1–based therapies in the treatment of obesity. |
Harold Bays |
| 03:10 PM | Diabetes Learning Objective Describe the mechanisms and clinical impact of GLP-1–based therapies on glycemic control in patients with obesity and diabetes. |
Alice Cheng |
| 03:25 PM | MASLD/MASH Learning Objective Summarize the emerging evidence on the effects of GLP-1–based therapies on metabolic dysfunction-associated steatotic liver disease (MASLD) and steatohepatitis (MASH). |
Mark Swain |
| 03:55 PM | Break | |
| 04:10 PM | Chronic kidney disease Learning Objective Describe the effects of GLP-1–based therapies on kidney outcomes in patients with obesity and chronic kidney disease. |
Louis-Philippe Girard |
| 04:25 PM | ASCVD Learning Objective Explain the impact of GLP-1–based therapies on atherosclerotic cardiovascular disease (ASCVD) risk in patients with obesity. |
Milan Gupta |
| 04:40 PM | Heart failure Learning Objective Evaluate the effects of GLP-1–based therapies on heart failure outcomes in patients with obesity. |
Mike Farkouh |
| 05:13 PM | Closing Keynote: Primary care: managing the interplay between obesity and cardiometabolic disease Learning Objective Identify and apply practical approaches for managing obesity-related cardiometabolic conditions in primary care, incorporating multidisciplinary strategies to optimize patient outcomes. |
Kim Colangelo |
| 05:45 PM | Meeting Close |
| Time | Topic | Speaker(s) |
|---|---|---|
| 12:00 PM | Welcome and opening remarks and guest speaker introductions | |
| 12:10 PM | Opening Keynote: The role of digital health in obesity management Learning Objective Describe how digital health technologies can support obesity management and patient engagement. |
Zayna Khayat |
| 12:45 PM | Is there a dietary fix for prediabetes? Learning Objective Explain the role of diet in the prevention and management of prediabetes and type 2 diabetes. |
Brendan Byrne |
| 01:03 PM | Ultraprocessed foods and industry reform Learning Objective Explain the impact of ultraprocessed foods on obesity and strategies for industry reform. |
Kevin Hall |
| 01:21 PM | Who will fund these drugs? The economics of preventative health Learning Objective Explain the economic challenges and considerations in funding preventive medications for obesity and related conditions. |
Kevin Pottie |
| 01:39 PM | Managing patients who cannot access GLP-1 based agents Learning Objective Identify alternative treatment options for patients unable to access GLP-1 receptor agonists. |
Trudy McFarlane |
| 02:22 PM | Break | |
| 02:57 PM | Reducing weight stigma Learning Objective Discuss strategies to reduce weight stigma and promote compassionate, patient-centered care. |
Taniya Nagpal |
| 03:15 PM | Hedonic eating - diagnosis and treatment Learning Objective Identify hedonic eating in patients and apply effective treatment strategies in clinical practice. |
David Macklin |
| 03:33 PM | Weight regain Learning Objective Identify key factors contributing to weight regain and strategies to address them. |
Tony Chetty |
| 03:51 PM | How to optimize dose titration Learning Objective Discuss practical strategies and monitoring approaches for safe and effective dose titration. |
Sandy Van |
| 04:39 PM | Guidelines dissemination: Challenges and Opportunities Learning Objective Identify barriers and strategies for successful implementation of obesity guidelines. |
Megha Poddar |
| 04:59 PM | Closing Keynote: New trials and new drugs: What we still have to learn Learning Objective Summarize recent obesity therapy trials and highlight remaining gaps in evidence. |
John Wilding |
| 05:35 PM | Meeting Close |
